Analyst Firm

Contact

Aegis Capital Corp.
810 Seventh Avenue, 18th Floor
New York, New York 10019
Robert LeBoyer
e-mail: RLeboyer@nullaegiscap.com
telephone: (646) 502-2494

Initiated: 09/07/16
Updated: 02/03/17
Maxim Group, LLC
405 Lexington Avenue
New York, NY 10174
Jason Kolbert
e-mail: jkolbert@nullmaximgrp.com
telephone: (212) 895-3516

Initiated: 09/24/13
Updated: 04/20/17
Zack's Investment Research, Inc.
111 North Canal Street
Chicago, IL, 60606
Grant Zeng, CFA
e-mail: gzeng@nullzacks.com
telephone: (312) 265-9466

Initiated: 06/26/13
Updated: 03/28/17
Aegis Capital Corp.
810 Seventh Avenue, 18th Floor
New York, New York 10019

Robert LeBoyer
e-mail: RLeboyer@nullaegiscap.com
telephone: (646) 502-2494

Initiated: 09/07/16
Updated: 02/03/17
Maxim Group, LLC
405 Lexington Avenue
New York, NY 10174

Jason Kolbert
e-mail: jkolbert@nullmaximgrp.com
telephone: (212) 895-3516

Initiated: 09/24/13
Updated: 04/20/17
Zack's Investment Research, Inc.
111 North Canal Street
Chicago, IL, 60606

Grant Zeng, CFA
e-mail: gzeng@nullzacks.com
telephone: (312) 265-9466

Initiated: 06/26/13
Updated: 03/28/17

Please note that any opinions, estimates or forecasts regarding Soligenix’s performance made by these analysts are theirs alone and do not represent the opinions, estimates or forecasts of Soligenix or its management. Soligenix does not by its reference above or by distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. By your uses of this website, you agree that you must evaluate and bear all risks associated with the use of any third-party content, including any reliance on the accuracy and completeness of such content.

Except for historical information, some of the statements set forth in the analysts’ reports constitute forward-looking statements regarding future events or the future financial performance of Soligenix. Words such as “expects,” “goals,” “plans,” “believes,” “may,” and variations of such words and similar expressions identify forward-looking statements. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in Soligenix’s filings with the U.S. Securities and Exchange Commission.